Changeflow GovPing Government & Legislation EU Regulation Banning Amalgam for Certain Patie...
Routine Notice Added Final

EU Regulation Banning Amalgam for Certain Patient Groups

Favicon for www.regulations.gov Regulations.gov Final Notices
Detected
Email

Summary

FDA published a notice on Regulations.gov (docket FDA-2026-P-4271) regarding an EU regulation that bans dental amalgam for certain patient groups. The EU measure restricts amalgam use for children under 15, and for pregnant or breastfeeding women. This notice informs U.S. stakeholders of the EU regulatory development affecting dental materials. The document provides a PDF download link to the EU regulation text.

Published by FDA on regulations.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

This feed pulls every final notice posted to regulations.gov across all federal agencies, around 240 a month. Final notices are the binding step in the federal rulemaking cycle: a final rule, a no-action determination, a self-regulatory organization rule change, or a procedural notice that takes effect on publication. Watch this for the actionable end of the rulemaking pipeline rather than the proposed-and-comment phase. GovPing publishes each notice with the issuing agency, docket ID, effective date where stated, and document type. Recent examples include Nasdaq ISE auction rule changes and an NYSE proposal enabling tokenized securities trading under the DTC pilot.

What changed

This document is an informational notice from FDA alerting stakeholders to a new EU regulation that restricts the use of dental amalgam for vulnerable patient populations. The EU measure prohibits amalgam dental restorations for children under 15 years of age and for pregnant or breastfeeding women, reflecting broader concerns about mercury exposure in these groups.

Dental material manufacturers, dental practices, and public health authorities operating internationally or exporting to the EU should review the EU regulatory requirements to assess compliance obligations. U.S. dental professionals treating EU-resident patients may also need to understand these restrictions when providing care.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Content

Download File

Download

Get daily alerts for Regulations.gov Final Notices

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Docket
FDA-2026-P-4271-0021

Who this affects

Applies to
Medical device makers Healthcare providers
Industry sector
3345 Medical Device Manufacturing
Activity scope
Regulatory compliance Medical device reporting
Geographic scope
European Union EU

Taxonomy

Primary area
Medical Devices
Operational domain
Compliance
Compliance frameworks
GxP
Topics
Healthcare Consumer Protection

Get alerts for this source

We'll email you when Regulations.gov Final Notices publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!